AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37950216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation intervention for 12 weeks
Number of subjects: 0
Study 37950216 — intervention group
Group type: COMPARATOR
Intervention: Educational session on HFpEF complications, functional decline, and healthy lifestyle habits for 12 weeks
Number of subjects: 0
Study 37950230 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Number of subjects: 36
Study 37950230 — intervention group
Group type: COMPARATOR
Intervention: Soft tissue mobilization with therapeutic exercises
Number of subjects: 36
Study 37950243 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnering for Change (P4C) intervention classes
Number of subjects: 400
Study 37950243 — intervention group
Group type: COMPARATOR
Intervention: Control classes
Number of subjects: 400
Study 37950301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling and omega-3 supplementation
Number of subjects: 50
Study 37950301 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study 37950338 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcenestrant 400 mg
Number of subjects: 95
Study 37950338 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcenestrant 200 mg
Number of subjects: 95
Study 37950338 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg
Number of subjects: 95
Study 37950370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin therapy
Number of subjects: 250
Study 37950370 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory and gustatory trainings
Number of subjects: 250
Study 37950390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 101
Study 37950392 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian (10/20/50 mg daily)
Number of subjects: 1746
Study 37950392 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard antiplatelet treatment
Number of subjects: 1746
Study 37950392 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian
Number of subjects: 1746
Study 37950393 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured active play intervention
Number of subjects: 15
Study 37950400 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare consultation
Number of subjects: 0
Study 37950400 — intervention group
Group type: COMPARATOR
Intervention: Usual in-person clinic consultation
Number of subjects: 0
Study 37950428 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel-bougie tracheotomy
Number of subjects: 30
Study 37950428 — intervention group
Group type: COMPARATOR
Intervention: Rapid-sequence tracheotomy
Number of subjects: 30
Study 37950533 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-type HPV genotype restriction
Number of subjects: 2969
Study 37950533 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 2969
Study 37950533 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy
Number of subjects: 2969
Study 37950533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 8-type HPV genotype restriction and VIA
Number of subjects: 2969
Study 37950612 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention with nutrition education and self-regulation skills curriculum
Number of subjects: 62
Study 37950612 — intervention group
Group type: COMPARATOR
Intervention: Location-triggered app messaging
Number of subjects: 62
Study 37950612 — intervention group
Group type: COMPARATOR
Intervention: Reflections on benefits of change with extra coaching time and tailored app messages
Number of subjects: 62
Study 37950612 — intervention group
Group type: COMPARATOR
Intervention: Coach monitoring of food purchases
Number of subjects: 62
Study 37950612 — intervention group
Group type: COMPARATOR
Intervention: Involvement of a household member
Number of subjects: 62
Study 37950674 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache attributed to influenza infection
Number of subjects: 75
Study 37950726 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil nasal spray 70 mg
Number of subjects: 69
Study 37950726 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 69
Study 37950897 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 628
Study 37950897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 37950897 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin avoidance
Number of subjects: 628
Study 37950907 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring with research physician-optimized antihypertensive titration
Number of subjects: 220
Study 37950907 — intervention group
Group type: COMPARATOR
Intervention: Usual postnatal care from a primary care physician and midwife
Number of subjects: 220
Study 37950918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (approximately 2200 mg sodium added daily to usual diet)
Number of subjects: 213
Study 37950918 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (approximately 500 mg daily total)
Number of subjects: 213
Study 37950918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet
Number of subjects: 213
Study 37950918 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 213
Study 37950919 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring along with physician-optimized antihypertensive titration
Number of subjects: 220
Study 37950919 — intervention group
Group type: COMPARATOR
Intervention: Usual postnatal care
Number of subjects: 220
Study 37951069 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program based on acceptance and commitment therapy
Number of subjects: 156
Study 37951069 — intervention group
Group type: COMPARATOR
Intervention: Health education leaflets (Control)
Number of subjects: 156
Study 37951218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy combined with toripalimab
Number of subjects: 22
Study 37951245 — intervention group
Group type: EXPERIMENTAL
Intervention: Orismilast 20 mg
Number of subjects: 202
Study 37951245 — intervention group
Group type: EXPERIMENTAL
Intervention: Orismilast 30 mg
Number of subjects: 202
Study 37951245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 37951292 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg plus Ezetimibe 10 mg (combination lipid-lowering therapy)
Number of subjects: 31993
Study 37951292 — intervention group
Group type: COMPARATOR
Intervention: High-intensity atorvastatin monotherapy
Number of subjects: 31993
Study 37951560 — intervention group
Group type: COMPARATOR
Intervention: Standard vedolizumab (300 mg every 8 weeks)
Number of subjects: 278
Study 37951560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-optimized vedolizumab (600 mg at week 6, then 300 mg every 4 weeks or 600 mg at week 6, then 600 mg every 4 weeks)
Number of subjects: 278
Study 37951560 — intervention group
Group type: COMPARATOR
Intervention: Standard vedolizumab
Number of subjects: 278
Study 37951560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-optimized vedolizumab
Number of subjects: 278
Study 37951571 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 249
Study 37951577 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality technology (SootheVR All-In-One virtual reality care system) during extra-amniotic balloon catheter insertion
Number of subjects: 132
Study 37951577 — intervention group
Group type: COMPARATOR
Intervention: Control group (institutional standard care)
Number of subjects: 132
Study 37951577 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality technology
Number of subjects: 132
Study 37951577 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 37951863 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PAS disorders and postpartum haemorrhage (PPH), n = 879
Number of subjects: 2029
Study 37951863 — intervention group
Group type: COMPARATOR
Intervention: Women with PAS disorders and normal blood loss, n = 1150
Number of subjects: 2029
Study 37951863 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for PPH in women with PAS disorders
Number of subjects: 2029
Study 37951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT)
Number of subjects: 879
Study 37951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated partial thromboplastin time (APTT)
Number of subjects: 879
Study 37951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen (FIB)
Number of subjects: 879
Study 37951881 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count
Number of subjects: 879
Study 37951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) count
Number of subjects: 879
Study 37951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 879
Study 37951900 — intervention group
Group type: EXPERIMENTAL
Intervention: End-on approach using multi-tined cannulae
Number of subjects: 72
Study 37951900 — intervention group
Group type: COMPARATOR
Intervention: Conventional parallel technique using straight cannulae
Number of subjects: 72
Study 37951903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention (half-day consultation based on a biopsychosocial model)
Number of subjects: 47
Study 37951954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg)
Number of subjects: 0
Study 37951954 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (200 mg)
Number of subjects: 0
Study 37951974 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 1859
Study 37951974 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1859
Study 37952030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac delivery of autologous CD34 cells
Number of subjects: 0
Study 37952085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HSCT + IV AAVrh10 at a dose of 4E13 gc/kg
Number of subjects: 0
Study 37952085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HSCT + IV AAVrh10 at a dose of 2E14 gc/kg
Number of subjects: 0
Study 37952085 — intervention group
Group type: COMPARATOR
Intervention: IV AAVrh10 alone
Number of subjects: 0
Study 37952085 — intervention group
Group type: COMPARATOR
Intervention: HSCT alone
Number of subjects: 0
Study 37952085 — intervention group
Group type: EXPERIMENTAL
Intervention: IV AAVrh10 alone or in addition to HSCT
Number of subjects: 0
Study 37952085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy at the highest dose
Number of subjects: 0
Study 37952114 — intervention group
Group type: EXPERIMENTAL
Intervention: NX-13 250 mg immediate release (IR)
Number of subjects: 38
Study 37952114 — intervention group
Group type: EXPERIMENTAL
Intervention: NX-13 500 mg immediate release (IR)
Number of subjects: 38
Study 37952114 — intervention group
Group type: EXPERIMENTAL
Intervention: NX-13 500 mg delayed release (DR)
Number of subjects: 38
Study 37952114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 37952114 — intervention group
Group type: EXPERIMENTAL
Intervention: NX-13 (all doses)
Number of subjects: 38
Study 37952131 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg, once-weekly subcutaneous)
Number of subjects: 17604
Study 37952131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604
Study 37952131 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 17604
Study 37952132 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily (2.5 mg twice daily when indicated)
Number of subjects: 4012
Study 37952132 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg daily
Number of subjects: 4012
Study 37952133 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin cutoff for transfusion, 7 or 8 g per deciliter)
Number of subjects: 3504
Study 37952133 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin cutoff, <10 g per deciliter)
Number of subjects: 3504
Study 37952170 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 11
Study 37952176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg per day
Number of subjects: 5788
Study 37952176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5788
Study 37952176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 5788
Study 37952180 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 529
Study 37952231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued group
Number of subjects: 18
Study 37952231 — intervention group
Group type: COMPARATOR
Intervention: Non-fatigued group
Number of subjects: 18
Study 37952254 — intervention group
Group type: EXPERIMENTAL
Intervention: lepodisiran 4 mg
Number of subjects: 48
Study 37952254 — intervention group
Group type: EXPERIMENTAL
Intervention: lepodisiran 12 mg
Number of subjects: 48
Study 37952254 — intervention group
Group type: EXPERIMENTAL
Intervention: lepodisiran 32 mg
Number of subjects: 48
Study 37952254 — intervention group
Group type: EXPERIMENTAL
Intervention: lepodisiran 96 mg
Number of subjects: 48
Study 37952254 — intervention group
Group type: EXPERIMENTAL
Intervention: lepodisiran 304 mg
Number of subjects: 48
Study 37952254 — intervention group
Group type: EXPERIMENTAL
Intervention: lepodisiran 608 mg
Number of subjects: 48
Study 37952254 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 37952338 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Low Back Pain (CLBP) group
Number of subjects: 202
Study 37952338 — intervention group
Group type: COMPARATOR
Intervention: Achilles Tendinopathy (AT) group
Number of subjects: 202
Study 37952548 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous oxytocin (infusion stopped beyond 6 cm dilation)
Number of subjects: 2170
Study 37952548 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin (administration continued until delivery)
Number of subjects: 2170
Study 37952550 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir
Number of subjects: 3290
Study 37952550 — intervention group
Group type: COMPARATOR
Intervention: Daily oral tenofovir disoproxil fumarate plus emtricitabine
Number of subjects: 3290
Study 37952714 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention
Number of subjects: 424
Study 37952714 — intervention group
Group type: COMPARATOR
Intervention: College required mental health screening and referral
Number of subjects: 424
Study 37952772 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram or escitalopram
Number of subjects: 255
Study 37952928 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation
Number of subjects: 504
Study 37952928 — intervention group
Group type: COMPARATOR
Intervention: Intermittent iron supplementation
Number of subjects: 504
Study 37952982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azacitidine (Oral-AZA) maintenance
Number of subjects: 238
Study 37952982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 37952982 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable hypomethylating agents as first subsequent therapy (FST) after Oral-AZA
Number of subjects: 238
Study 37952982 — intervention group
Group type: COMPARATOR
Intervention: Injectable hypomethylating agents as first subsequent therapy (FST) after placebo
Number of subjects: 238
Study 37953075 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone oral suspension (105 mg in 5 mL aqueous suspension) administered orally
Number of subjects: 15
Study 37953075 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone oral suspension (105 mg in 5 mL aqueous suspension) administered via PEG tube
Number of subjects: 15
Study 37953500 — intervention group
Group type: EXPERIMENTAL
Intervention: Linerixibat 40 mg b.i.d.
Number of subjects: 0
Study 37953500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37953503 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing techniques including a POI-associated gene panel, extended whole exome sequencing data, and specific autoantibody assays.
Number of subjects: 100
Study 37953503 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended diagnostic investigations including screening for chromosomal anomalies and FMR1 premutations.
Number of subjects: 100
Study 37953814 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib (25 mg) for up to 10 days
Number of subjects: 28
Study 37953814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 37953814 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib
Number of subjects: 28
Study 37954037 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus platinum-based chemotherapy (arm A)
Number of subjects: 0
Study 37954037 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy (arm C)
Number of subjects: 0
Study 37954068 — intervention group
Group type: EXPERIMENTAL
Intervention: H3L6 diet (high omega-3, low omega-6 diet)
Number of subjects: 182
Study 37954068 — intervention group
Group type: EXPERIMENTAL
Intervention: H3 diet (high omega-3, average omega-6 diet)
Number of subjects: 182
Study 37954068 — intervention group
Group type: COMPARATOR
Intervention: Control diet (average intakes of omega-3 and omega-6 fatty acids)
Number of subjects: 182
Study 37954548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (2 × 4-min high-intensity treadmill exercise at 85%-90% of peak heart rate, 3-min active recovery)
Number of subjects: 72
Study 37954548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume HIIT (4 × 4-min high-intensity treadmill exercise at 85%-90% of peak heart rate, three 3-min active recovery)
Number of subjects: 72
Study 37954548 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 72
Study 37954892 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TMT-B scores
Number of subjects: 841
Study 37954892 — intervention group
Group type: EXPERIMENTAL
Intervention: TMT-B as a stand-alone test
Number of subjects: 841
Study 37954898 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic and clinical epidemiology of PCSK9 inhibition
Number of subjects: 9
Study 37954898 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibition
Number of subjects: 9
Study 37954898 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive, pretreatment settings of PCSK9 inhibition
Number of subjects: 9
Study 37954906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegmolesatide (administered once every four weeks)
Number of subjects: 372
Study 37954906 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (administered one to three times per week)
Number of subjects: 372
Study 37954906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegmolesatide
Number of subjects: 372
Study 37954906 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 372
Study 37954964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus etoposide and platinum (EP)
Number of subjects: 439
Study 37954964 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus etoposide and platinum (EP)
Number of subjects: 439
Study 37955005 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly somatrogon
Number of subjects: 24
Study 37955005 — intervention group
Group type: COMPARATOR
Intervention: Once-daily rhGH
Number of subjects: 24
Study 37955353 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 4571
Study 37955353 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 4571
Study 37955439 — intervention group
Group type: EXPERIMENTAL
Intervention: Management protocol based on ICP monitoring
Number of subjects: 0
Study 37955439 — intervention group
Group type: COMPARATOR
Intervention: Management protocol based on imaging and clinical examination without ICP monitoring
Number of subjects: 0
Study 37955445 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable measure of physical activity monitoring using Apple Watch
Number of subjects: 65
Study 37955580 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero enzyme replacement therapy (IUERT)
Number of subjects: 0
Study 37955580 — intervention group
Group type: COMPARATOR
Intervention: Postnatal enzyme replacement therapy (ERT)
Number of subjects: 0
Study 37955615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle walking intervention combining self-monitoring and regular telephone counseling
Number of subjects: 202
Study 37955615 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study 37955644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Insulin Management
Number of subjects: 0
Study 37955741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg orally as intact capsules with a nutritional supplement
Number of subjects: 58
Study 37955741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib contents dispersed in a nutritional supplement via nasogastric tube
Number of subjects: 58
Study 37955741 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dose of 200 mg orally twice daily as intact capsules with a nutritional supplement
Number of subjects: 58
Study 37955745 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal steroids (betamethasone, hydrocortisone hemisuccinate)
Number of subjects: 192
Study 37955745 — intervention group
Group type: COMPARATOR
Intervention: No postnatal steroids (control group)
Number of subjects: 192
Study 37955825 — intervention group
Group type: COMPARATOR
Intervention: Sotrovimab 500 mg IV infusion
Number of subjects: 0
Study 37955825 — intervention group
Group type: COMPARATOR
Intervention: Sotrovimab 500 mg IM dose
Number of subjects: 0
Study 37955825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37955849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) insulin delivery system
Number of subjects: 65
Study 37955923 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care education for community neurologists and team-based palliative care support via telehealth
Number of subjects: 359